E
Tier
Myostatin-inhibiting protein for muscle growth.
Protein, not a peptide
WADA Status:
Prohibited at all times (S4.3)
Human Trial Scoreboard
Completed human RCTs
None for the protein
Largest Human Study
Gene therapy is a different product
Longest exposure
None studied
Most Recent Trial
No completed trial
Description
Follistatin is a protein that binds and neutralises myostatin, the body's own brake on muscle growth, which makes it an obvious target for anyone interested in muscle. The genuinely impressive follistatin research is gene therapy: delivering the gene so the body produces the protein itself, tested in academic centres for muscular dystrophy. That is not what is sold as Follistatin-344. The injectable protein is a different product entirely, with no completed human trial behind it, and the gene therapy results do not transfer to it. Sustained interference with myostatin also raises real questions about effects on tendon and connective tissue, since muscle strength gained faster than supporting structures adapt is not obviously desirable.
What Are The Claims
Claims made for this compound: Releases the myostatin brake on muscle
Evidence
Myostatin inhibition produces dramatic results in animal models, which drives the marketing. Systemic follistatin has broad biological roles beyond muscle, and the consequences of manipulating it in humans are uncharacterized.
Evidence Strength
Animal/preclinical only (gene-therapy trials are a different product)
Caveats
Safety
Alternative Measures
Legal Status
US
Not approved
UK
Not approved
EU
Not approved
AU
Not approved
WADA
Prohibited at all times (S4.3)
Not approved. Research chemical. WADA-prohibited.
Citations
No completed peer-reviewed human clinical trial exists for this compound. Where a citation is absent below, that absence is the finding.